A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).
2019
11017Background: Most
GISTsare driven by mutations in KIT and
PDGFRaand secondary mutations are
feltto confer resistance to TKIs. In advanced/metastatic
GIST, the benefit of second line TKIs and...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
10
Citations
NaN
KQI